Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) dropped 3% during trading on Wednesday . The stock traded as low as $14.83 and last traded at $15.10, with a volume of 61,659 shares. The stock had previously closed at $15.56.

Separately, Zacks Investment Research cut Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th.

The stock’s market cap is $157.01 million. The company has a 50 day moving average of $12.78 and a 200 day moving average of $10.82.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/dipexium-pharmaceuticals-inc-dprx-trading-down-3.html

Dipexium Pharmaceuticals (NASDAQ:DPRX) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.02. Equities analysts expect that Dipexium Pharmaceuticals Inc. will post ($2.10) EPS for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of DPRX. Lombard Odier Asset Management USA Corp acquired a new position in Dipexium Pharmaceuticals during the second quarter valued at about $1,507,000. Goldman Sachs Group Inc. acquired a new position in Dipexium Pharmaceuticals during the first quarter valued at about $1,062,000. Emerald Acquisition Ltd. acquired a new position in Dipexium Pharmaceuticals during the second quarter valued at about $854,000. Raymond James & Associates acquired a new position in Dipexium Pharmaceuticals during the second quarter valued at about $312,000. Finally, Timpani Capital Management LLC raised its position in Dipexium Pharmaceuticals by 45.4% in the second quarter. Timpani Capital Management LLC now owns 64,124 shares of the company’s stock valued at $635,000 after buying an additional 20,014 shares during the period. 24.78% of the stock is owned by hedge funds and other institutional investors.

About Dipexium Pharmaceuticals

Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).

5 Day Chart for NASDAQ:DPRX

Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.